Last reviewed · How we verify
NCT03168815
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy
NA trial testing High Flow Nasal Cannula or Low Flow Nasal Cannula in Immunocompromised in 98 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Mount Sinai Hospital, Canada |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 98 |
| Start date | 10 January 2018 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- High Flow Nasal Cannula or Low Flow Nasal Cannula
Conditions studied
- Immunocompromised — all drugs for Immunocompromised →
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
- Post Hematopoietic Stem Cell Transplant — all drugs for Post Hematopoietic Stem Cell Transplant →
- Hypoxia — all drugs for Hypoxia →
Sponsor
Mount Sinai Hospital, Canada
Who can join
18 and older, any sex, with Immunocompromised or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pneumonia is a lung infection. Fiberoptic bronchoscopy is a test to diagnose the type of lung infection. While this procedure is being performed, a small amount of oxygen is delivered into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen of the patient may drop and an intervention such as increasing the oxygen flow, or placing the patient on a breathing machine is required. An alternative device called 'Optiflow' can provide high flow oxygen through nasal cannula, and is comfortable for patients. If Optiflow is used during bronchoscopy, it may prevent the blood oxygen from dropping.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03168815
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunocompromised
Currently open trials in the same condition.
- NCT07120464 — Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations · recruiting
- NCT03808922 — Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study · Phase 3 · recruiting
- NCT03425526 — Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease · Phase 1 · recruiting
Other Mount Sinai Hospital, Canada trials
Trials by the same sponsor.
- NCT07272460 — Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial · NA · recruiting
- NCT07046572 — Methoxyflurane for IUD Insertion and Endometrial Biopsy · NA · recruiting
- NCT06504277 — Low Versus Standard Pressure Pneumoperitoneum on Shoulder Tip Pain · NA · recruiting
- NCT06546254 — 1% Lidocaine Paracervical Block for Endometrial Biopsy · NA · completed
- NCT06733701 — The Use of Virtual Reality Technology During Oocyte Retrieval for in Vitro Fertilization · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03168815 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mount Sinai Hospital, Canada
- Last refreshed: 9 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03168815.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing